ReviewAnnals of biomedical engineering2026
The Application of 3D Cell Culture in Thyroid Cancer.
Review in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Thyroid cancer is the most prevalent endocrine malignancy and displays pronounced heterogeneity in histology, molecular alterations, and therapeutic responses, particularly in poorly differentiated, anaplastic, and radioiodine-refractory disease. Conventional two-dimensional cultures and animal models inadequately recapitulate the three-dimensional (3D) architecture, tumor microenvironment, and thyroid-specific functions, limiting their translational relevance. Recent advances in 3D culture technologies, especially organoid models, have provided physiologically relevant platforms for in vitro thyroid cancer research. This review summarizes current strategies for constructing thyroid cancer 3D models, with emphasis on spheroid and organoid systems, encompassing scaffold-free, scaffold-based cultures, and emerging bioengineering platforms such as dynamic bioreactors, decellularized extracellular matrices, microfluidic organ-on-a-chip systems, and 3D bioprinting. We further highlight key applications of thyroid cancer organoids in disease modeling, drug screening, radioiodine response prediction, and personalized therapeutic evaluation and discuss remaining challenges and future directions toward improved standardization and clinical translation. Compared with previous reviews on thyroid 3D culture, this work provides a more integrated and updated perspective by systematically linking culture strategies with tumor microenvironmental complexity, functional thyroid phenotypes, and emerging translational platforms, thereby offering a comprehensive framework for next-generation thyroid cancer modeling.
Indexed as
Identifiers
42496939What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.